BetterLife Pharma (TSE:BETR) has released an update.
BetterLife Pharma Inc. has amended beneficial ownership information in past Management Information Circulars and announced the issuance of new shares and warrants following a convertible debentures conversion. The biotech company is advancing the development of non-hallucinogenic compounds, BETR-001 and BETR-002, aimed at treating various neuropsychiatric and neurological disorders.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.
